Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy

A multicenter study from Japan

Japanese study group for pregnant women with IBD

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background/Aims: Anti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy. However, there are limited data on the benefit/risk profile of anti-TNF and thiopurines during pregnancy in Asia. The aim of this study was to analyze pregnancy outcomes of female Japanese IBD patients treated with anti-TNF and/or thiopurines. Methods: This cross-sectional study assessed pregnancy outcomes in 72 women with IBD. Pregnancy outcomes were compared among 31 pregnancies without exposure to infliximab (IFX), adalimumab (ADA), or thiopurines; 24 pregnancies with exposure to anti-TNF treatment (23 IFX, 1 ADA); 7 pregnancies with exposure to thiopurines alone; and 10 pregnancies with exposure to both IFX and thiopurines. Results: Thirty-five of the 41 pregnancies (85.3%) that were exposed to anti-TNF treatment and/or thiopurines resulted in live births after a median gestational period of 38 weeks. Of the 35 live births, 3 involved premature deliveries; 7, low birth weight; and 1, a congenital abnormality. There were 6 spontaneous abortions in pregnancies that were exposed to anti-TNF treatment (17.7%). Pregnancy outcomes among the 4 groups were similar, except for the rate of spontaneous abortions (P =0.037). Conclusions: Exposure to anti-TNF treatment or thiopurines during pregnancy was not related to a higher incidence of adverse pregnancy outcomes in Japanese IBD patients except for spontaneous abortion.

Original languageEnglish
Pages (from-to)139-145
Number of pages7
JournalIntestinal Research
Volume14
Issue number2
DOIs
Publication statusPublished - 2016

Fingerprint

Pregnancy Outcome
Inflammatory Bowel Diseases
Multicenter Studies
Japan
Tumor Necrosis Factor-alpha
Pregnancy
Pharmaceutical Preparations
Spontaneous Abortion
Therapeutics
Live Birth
Low Birth Weight Infant
Cross-Sectional Studies
Incidence

Keywords

  • Anti tumor necrosis factor-alpha
  • Inflammatory bowel diseases
  • Pregnancy outcome
  • Thiopurines

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy : A multicenter study from Japan. / Japanese study group for pregnant women with IBD.

In: Intestinal Research, Vol. 14, No. 2, 2016, p. 139-145.

Research output: Contribution to journalArticle

@article{0c78713867ed4e8fa1a35741b6fe2b4b,
title = "Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: A multicenter study from Japan",
abstract = "Background/Aims: Anti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy. However, there are limited data on the benefit/risk profile of anti-TNF and thiopurines during pregnancy in Asia. The aim of this study was to analyze pregnancy outcomes of female Japanese IBD patients treated with anti-TNF and/or thiopurines. Methods: This cross-sectional study assessed pregnancy outcomes in 72 women with IBD. Pregnancy outcomes were compared among 31 pregnancies without exposure to infliximab (IFX), adalimumab (ADA), or thiopurines; 24 pregnancies with exposure to anti-TNF treatment (23 IFX, 1 ADA); 7 pregnancies with exposure to thiopurines alone; and 10 pregnancies with exposure to both IFX and thiopurines. Results: Thirty-five of the 41 pregnancies (85.3{\%}) that were exposed to anti-TNF treatment and/or thiopurines resulted in live births after a median gestational period of 38 weeks. Of the 35 live births, 3 involved premature deliveries; 7, low birth weight; and 1, a congenital abnormality. There were 6 spontaneous abortions in pregnancies that were exposed to anti-TNF treatment (17.7{\%}). Pregnancy outcomes among the 4 groups were similar, except for the rate of spontaneous abortions (P =0.037). Conclusions: Exposure to anti-TNF treatment or thiopurines during pregnancy was not related to a higher incidence of adverse pregnancy outcomes in Japanese IBD patients except for spontaneous abortion.",
keywords = "Anti tumor necrosis factor-alpha, Inflammatory bowel diseases, Pregnancy outcome, Thiopurines",
author = "{Japanese study group for pregnant women with IBD} and Shunsuke Komoto and Satoshi Motoya and Yuji Nishiwaki and Toshiyuki Matsui and Reiko Kunisaki and Katsuyoshi Matsuoka and Naoki Yoshimura and Takashi Kagaya and Makoto Naganuma and Nobuyuki Hida and Mamoru Watanabe and Toshifumi Hibi and Yasuo Suzuki and Soichiro Miura and Ryota Hokari and Kozue Tsurumi and Shinji Tanaka and Yoshitaka Ueno and Shiro Nakamura and Kazuya Kitamura and Hiroshi Nakase and Minoru Matsuura and Takuya Yoshino and Motohiro Esaki and Chie Kurihara and Hirokazu Sato and Masaaki Higashiyama and Kenichi Yoshikawa and Chikako Watanabe and Kenji Watanabe and Kenji Fujimori and Hiroki Tanaka and Shunji Ishihara and Akira Sugita",
year = "2016",
doi = "10.5217/ir.2016.14.2.139",
language = "English",
volume = "14",
pages = "139--145",
journal = "Intestinal Research",
issn = "1598-9100",
publisher = "Korean Association for the Study of Intestinal Diseases",
number = "2",

}

TY - JOUR

T1 - Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy

T2 - A multicenter study from Japan

AU - Japanese study group for pregnant women with IBD

AU - Komoto, Shunsuke

AU - Motoya, Satoshi

AU - Nishiwaki, Yuji

AU - Matsui, Toshiyuki

AU - Kunisaki, Reiko

AU - Matsuoka, Katsuyoshi

AU - Yoshimura, Naoki

AU - Kagaya, Takashi

AU - Naganuma, Makoto

AU - Hida, Nobuyuki

AU - Watanabe, Mamoru

AU - Hibi, Toshifumi

AU - Suzuki, Yasuo

AU - Miura, Soichiro

AU - Hokari, Ryota

AU - Tsurumi, Kozue

AU - Tanaka, Shinji

AU - Ueno, Yoshitaka

AU - Nakamura, Shiro

AU - Kitamura, Kazuya

AU - Nakase, Hiroshi

AU - Matsuura, Minoru

AU - Yoshino, Takuya

AU - Esaki, Motohiro

AU - Kurihara, Chie

AU - Sato, Hirokazu

AU - Higashiyama, Masaaki

AU - Yoshikawa, Kenichi

AU - Watanabe, Chikako

AU - Watanabe, Kenji

AU - Fujimori, Kenji

AU - Tanaka, Hiroki

AU - Ishihara, Shunji

AU - Sugita, Akira

PY - 2016

Y1 - 2016

N2 - Background/Aims: Anti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy. However, there are limited data on the benefit/risk profile of anti-TNF and thiopurines during pregnancy in Asia. The aim of this study was to analyze pregnancy outcomes of female Japanese IBD patients treated with anti-TNF and/or thiopurines. Methods: This cross-sectional study assessed pregnancy outcomes in 72 women with IBD. Pregnancy outcomes were compared among 31 pregnancies without exposure to infliximab (IFX), adalimumab (ADA), or thiopurines; 24 pregnancies with exposure to anti-TNF treatment (23 IFX, 1 ADA); 7 pregnancies with exposure to thiopurines alone; and 10 pregnancies with exposure to both IFX and thiopurines. Results: Thirty-five of the 41 pregnancies (85.3%) that were exposed to anti-TNF treatment and/or thiopurines resulted in live births after a median gestational period of 38 weeks. Of the 35 live births, 3 involved premature deliveries; 7, low birth weight; and 1, a congenital abnormality. There were 6 spontaneous abortions in pregnancies that were exposed to anti-TNF treatment (17.7%). Pregnancy outcomes among the 4 groups were similar, except for the rate of spontaneous abortions (P =0.037). Conclusions: Exposure to anti-TNF treatment or thiopurines during pregnancy was not related to a higher incidence of adverse pregnancy outcomes in Japanese IBD patients except for spontaneous abortion.

AB - Background/Aims: Anti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy. However, there are limited data on the benefit/risk profile of anti-TNF and thiopurines during pregnancy in Asia. The aim of this study was to analyze pregnancy outcomes of female Japanese IBD patients treated with anti-TNF and/or thiopurines. Methods: This cross-sectional study assessed pregnancy outcomes in 72 women with IBD. Pregnancy outcomes were compared among 31 pregnancies without exposure to infliximab (IFX), adalimumab (ADA), or thiopurines; 24 pregnancies with exposure to anti-TNF treatment (23 IFX, 1 ADA); 7 pregnancies with exposure to thiopurines alone; and 10 pregnancies with exposure to both IFX and thiopurines. Results: Thirty-five of the 41 pregnancies (85.3%) that were exposed to anti-TNF treatment and/or thiopurines resulted in live births after a median gestational period of 38 weeks. Of the 35 live births, 3 involved premature deliveries; 7, low birth weight; and 1, a congenital abnormality. There were 6 spontaneous abortions in pregnancies that were exposed to anti-TNF treatment (17.7%). Pregnancy outcomes among the 4 groups were similar, except for the rate of spontaneous abortions (P =0.037). Conclusions: Exposure to anti-TNF treatment or thiopurines during pregnancy was not related to a higher incidence of adverse pregnancy outcomes in Japanese IBD patients except for spontaneous abortion.

KW - Anti tumor necrosis factor-alpha

KW - Inflammatory bowel diseases

KW - Pregnancy outcome

KW - Thiopurines

UR - http://www.scopus.com/inward/record.url?scp=85006041203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006041203&partnerID=8YFLogxK

U2 - 10.5217/ir.2016.14.2.139

DO - 10.5217/ir.2016.14.2.139

M3 - Article

VL - 14

SP - 139

EP - 145

JO - Intestinal Research

JF - Intestinal Research

SN - 1598-9100

IS - 2

ER -